Wall Street In Focus: AGCO Corporation (AGCO), Vapor Group (VPOR), OXiGENE (OXGN)

AGCO Corporation (NYSE:AGCO) narrowed its 2014 earnings outlook such that it now expects to earn between $4.10 and $4.30 per share. The reduction of the EPS outlook triggered analysts at Goldman Sachs Group Inc (NYSE:GS) to chop their target on the stock price of AGCO. The analysts maintained the stock on a “sell” list but chopped the target to $36 from $48. AGCO last reported quarterly earnings in July, during which its beat EPS estimates, but fell short of the revenue expectation. The company earned $1.77 per share, ahead of the estimate of $1.70. Revenue was $2.75 billion, down 9.8% YoY and also missed the consensus estimate of $2.81 billion. AGCO carries consensus rating of “hold” and average target price of $53.43.

Vapor Group Inc (OTCMKTS:VPOR) has about $2.6 million of notes that are waiting to be converted into common stock. That means an eminent continued dilution of the stock that has already seen massively dilution in the recent times. There are also rumors that another round of promotion is just around the corner. The promoter has reportedly received $200,000 to do the work for artificial hype. These issues somehow mask the important developments in Vapor Group Inc (OTCMKTS:VPOR) such as growing revenue, solid business performance and new products. As such, investors are good to keep a closer eye on the stock, especially with regards to dilution and the artificial hype.

OXiGENE Inc (NASDAQ:OXGN) has announced the enrollment of the first subject in its Phase 1b/2 clinical trial of Fosbretabulin. The study will evaluate the experimental drug in combination with Votrient. The focus of the study is patients suffering from recurrent ovarian cancer. Votrient is an approved cancer treatment from GlaxoSmithKline PLC (NYSE:GSK). At least 128 patients are expected to be enrolled in the study. The clinical trial will be conducted at various sites in the U.K. OXGN said the primary endpoint of the study is progression free-survival. However, the secondary endpoint will focus on the safety of the treatment and response rate.

About the Author

Stinson is US Markets Daily’s Senior Producer for News & Public Affairs.

Leave A Response